In an advance for precision oncology, the largest published study to date on molecular residual disease (MRD) detection in stage 3 colon cancer has demonstrated the prognostic capabilities of Guardant ...

Please provide your email address to receive an email when new articles are posted on . The detection of specific genomic alterations in circulating tumor DNA appeared linked to poorer outcomes among ...

ctDNA detection has advanced, allowing identification of minimal residual disease and predicting cancer recurrence with high sensitivity. Liquid biopsies offer a minimally invasive method to analyze ...

In this review, the researchers highlighted the potential of ctDNA profiling in lymphoma management, including diagnosis, treatment response evaluation, and risk stratification. By analyzing DNA ...

Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small cell lung cancer with ctDNA positivity after chemotherapy had significant ...

There are multiple potential applications for circulating tumor (ct)DNA in kidney cancer. The post-nephrectomy remission, adjuvant therapy decision, and monitoring for response or progression on ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study ctDNA was detected in 24.5% of ...

CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company’s NeXT Personal test, ...